{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:47:19Z","timestamp":1783079239550,"version":"3.54.6"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>With shifting epidemiology and changes in the vaccine funding landscape, resource use considerations for COVID-19 vaccination programs are increasingly important.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the cost effectiveness of COVID-19 vaccination programs, where eligibility is defined by combinations of age and chronic medical conditions, including a strategy similar to current Canadian recommendations.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Static, individual-based, probabilistic cost-utility model economic evaluation parameterized with recent data describing COVID-19 epidemiology, vaccine characteristics, and costs. The analysis used a 15-month time horizon from July 2024 to September 2025 and a modeled cohort of 1 million people with characteristics based on the Canadian population, stratified by age group and presence or absence of at least 1 chronic medical condition.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Annual or biannual COVID-19 vaccination strategies offered to different age and medical risk groups, with annual vaccination occurring in October and November in the primary analysis.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Medically attended SARS-CoV-2 infections treated in outpatient and inpatient settings, including post-COVID condition cases and deaths. Costs in 2023 Canadian dollars, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs), discounted at 1.5% for the health system and societal perspectives.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 1 million simulated individuals, annual vaccination for adults aged 65 years and older consistently emerged as a cost-effective intervention, with ICERs less than CAD $50\u202f000 per QALY compared with no vaccination for a range of model assumptions. Adding a second dose for adults aged 65 years and older or expanding programs to include vaccination for younger age groups, including those at higher risk of COVID-19 due to chronic medical conditions, generally resulted in ICERs greater than $50\u202f000 per QALY. Shifting timing of vaccination programs to better align with periods of high COVID-19 case occurrence resulted in biannual vaccination for those aged 65 years and older being cost effective.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this economic evaluation of COVID-19 vaccination strategies, programs were observed to be cost effective when focused on groups at higher risk of disease. Optimal timing of programs improved the cost effectiveness of vaccination strategies. As COVID-19 transitioned to an endemic disease with high levels of population immunity, many jurisdictions revisited COVID-19 vaccination recommendations; these results identified COVID-19 vaccination programs that may provide good value for money.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.15534","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T15:30:36Z","timestamp":1749828636000},"page":"e2515534","source":"Crossref","is-referenced-by-count":8,"title":["Cost-Utility Analysis of COVID-19 Vaccination Strategies for Endemic SARS-CoV-2"],"prefix":"10.1001","volume":"8","author":[{"given":"Rafael N.","family":"Miranda","sequence":"first","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison E.","family":"Simmons","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W. Z.","family":"Li","sequence":"additional","affiliation":[{"name":"Public Health Risk Sciences Division, National Microbiology Laboratory, Public Health Agency of Canada, Guelph, Ontario, Canada"},{"name":"Department of Mathematics and Statistics, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebremedhin B.","family":"Gebretekle","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xi","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina I.","family":"Salvadori","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"},{"name":"Department of Pediatrics, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryna","family":"Warshawsky","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"},{"name":"Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wong","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Ximenes","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Andrew","sequence":"additional","affiliation":[{"name":"Department of Medicine (Geriatrics), Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Sander","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Max Rady College of Medicine, University of Manitoba, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wilson","sequence":"additional","affiliation":[{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Tunis","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh R.","family":"Tuite","sequence":"additional","affiliation":[{"name":"Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"zoi250497r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100747","author":"Evans","year":"2023","journal-title":"The Lancet Regional Health\u2014Europe"},{"issue":"42","key":"zoi250497r4","doi-asserted-by":"publisher","first-page":"E1427","DOI":"10.1503\/cmaj.230721","article-title":"Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada.","volume":"195","author":"Skowronski","year":"2023","journal-title":"CMAJ"},{"key":"zoi250497r5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076222","article-title":"Long term risk of death and readmission after hospital admission with covid-19 among older adults: retrospective cohort study.","volume":"382","author":"Oseran","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"zoi250497r6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.14745\/ccdr.v49i06a03","article-title":"Quantifying the economic gains associated with COVID-19 vaccination in the Canadian population: a cost-benefit analysis.","volume":"49","author":"Tuite","year":"2023","journal-title":"Can Commun Dis Rep"},{"issue":"11","key":"zoi250497r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43127","article-title":"Return on investment of the COVID-19 vaccination campaign in New York City.","volume":"5","author":"Sah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi250497r8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"zoi250497r10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","article-title":"Early estimates of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults\u2014increasing community access to testing program, United States, September 2023-January 2024.","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi250497r11","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.1.2300703","article-title":"Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023.","volume":"29","author":"van Werkhoven","year":"2024","journal-title":"Euro Surveill"},{"issue":"1","key":"zoi250497r16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"29","key":"zoi250497r17","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.240452","article-title":"Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis.","volume":"196","author":"Tuite","year":"2024","journal-title":"CMAJ"},{"issue":"8","key":"zoi250497r35","first-page":"567","article-title":"Opportunity costs of ambulatory medical care in the United States.","volume":"21","author":"Ray","year":"2015","journal-title":"Am J Manag Care"},{"issue":"16","key":"zoi250497r38","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.vaccine.2009.02.024","article-title":"A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population.","volume":"27","author":"Lee","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"zoi250497r43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000256","article-title":"Economic appraisal of Ontario\u2019s universal influenza immunization program: a cost-utility analysis.","volume":"7","author":"Sander","year":"2010","journal-title":"PLoS Med"},{"issue":"9","key":"zoi250497r48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202787","article-title":"Health care costs of influenza-related episodes in high income countries: a systematic review.","volume":"13","author":"Federici","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"zoi250497r49","article-title":"Nirmatrelvir-Ritonavir (Paxlovid).","volume":"4","author":"Reimbursement Recommendation","year":"2024","journal-title":"Can J Health Technol"},{"issue":"5","key":"zoi250497r50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jval.2022.06.014","article-title":"Caregiving-related work productivity loss among employed family and other unpaid caregivers of older adults.","volume":"26","author":"Keita Fakeye","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"zoi250497r52","first-page":"29","article-title":"Health Utilities Index Mark 3 scores for children and youth: population norms for Canada based on cycles 5 (2016 and 2017) and 6 (2018 and 2019) of the Canadian Health Measures Survey.","volume":"34","author":"Molina","year":"2023","journal-title":"Health Rep"},{"issue":"1","key":"zoi250497r53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10198-023-01570-1","article-title":"Canada population norms for the EQ-5D-5L.","volume":"25","author":"Yan","year":"2024","journal-title":"Eur J Health Econ"},{"issue":"7","key":"zoi250497r55","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1473-3099(21)00079-7","article-title":"The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.","volume":"21","author":"Sandmann","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"zoi250497r60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40258-021-00683-z","article-title":"Towards a broader assessment of value in vaccines: the BRAVE way forward.","volume":"20","author":"Bell","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"key":"zoi250497r41","author":"O\u2019Reilly","year":"2017"},{"key":"zoi250497r1","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard: Deaths. Accessed October 21, 2024. https:\/\/data.who.int\/dashboards\/covid19\/deaths"},{"key":"zoi250497r2","unstructured":"World Health Organization. WHO director-general\u2019s opening remarks at the media briefing\u20145 May 2023. Accessed October 21, 2024. https:\/\/www.who.int\/news-room\/speeches\/item\/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023"},{"key":"zoi250497r9","unstructured":"Wyonch? R, Zhang? T. Damage averted: estimating the effects of Covid-19 vaccines on hospitalizations, mortality and costs in Canada. C.D. Howe Institute. Accessed December 12, 2024. https:\/\/www.cdhowe.org\/sites\/default\/files\/2023-01\/Commentary_634.pdf"},{"key":"zoi250497r12","unstructured":"Government of Canada. People who are at risk of more severe disease or outcomes from COVID-19. Updated April 22, 2022. Accessed November 12, 2024. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/diseases-conditions\/people-high-risk-for-severe-illness-covid-19\/people-high-risk-for-severe-illness-covid-19-eng.pdf"},{"key":"zoi250497r13","unstructured":"National Advisory Committee on Immunization. Guidance on the use of COVID-19 vaccines during the fall of 2024. Accessed November 24, 2024. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-guidance-covid-19-vaccines-fall-2024\/naci-statement-2024-05-03.pdf"},{"key":"zoi250497r14","unstructured":"National Advisory Committee on Immunization. Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19. Accessed November 24, 2024. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-guidance-additional-dose-covid-19-vaccines-spring-2024-individuals-high-risk-severe-illness-due-covid-19\/naci-statement-2024-01-12.pdf"},{"key":"zoi250497r15","unstructured":"National Advisory Committee on Immunization (NACI). Guidelines for the economic evaluation of vaccination programs in Canada. Accessed November 24, 2024. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-committee-on-immunization-naci\/methods-process\/incorporating-economic-evidence-federal-vaccine-recommendations\/guidelines-evaluation-vaccination-programs-canada.pdf"},{"key":"zoi250497r18","unstructured":"Queenan? JA, Wong? ST, Barber? D, Morkem? R, Salman? A. The prevalence of common chronic conditions seen in Canadian primary care: results from the Canadian Primary Care Sentinel Surveillance Network. 2021. Canadian Primary Care Sentinel Surveillance Network. Accessed May 9, 2025. https:\/\/cpcssn.ca\/wp-content\/uploads\/2021\/05\/cpcssn-chronic-conditions-report-2021.pdf"},{"key":"zoi250497r19","unstructured":"Statistics Canada. Table 13-10-0777-01. Number and percentage of adults (aged 18 years and older) in the household population with underlying health conditions, by age and sex (two-year period) .Accessed January 5, 2024. doi:10.25318\/1310077701-eng"},{"key":"zoi250497r20","unstructured":"Prosser? LA. Economic analysis of COVID-19 vaccination. Slides presented at Advisory Committee on Immunization Practices (ACIP) meeting. June 24, 2024. Accessed November 14, 2024. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2024-06-26-28\/05-COVID-Prosser-508.pdf"},{"key":"zoi250497r21","unstructured":"Centers for Disease Control and Prevention (CDC). Underlying conditions and the higher risk for severe COVID-19. Updated July 30, 2024. Accessed August 01, 2024. https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html"},{"key":"zoi250497r22","unstructured":"Statistics Canada. Table 17-10-0057-01. Projected population, by projection scenario, age and sex, as of July 1 (x 1,000). Accessed July 24, 2024. doi:10.25318\/1710005701-eng"},{"key":"zoi250497r23","unstructured":"Statistics Canada. Table 13-10-0777-01 number and percentage of adults (aged 18 years and older) in the household population with underlying health conditions, by age and sex (two-year period). Accessed October 28, 2024. doi:10.25318\/1310077701-eng"},{"key":"zoi250497r24","unstructured":"Government of Canada. COVID-19 epidemiology update. Accessed July 31, 2024. https:\/\/health-infobase.canada.ca\/covid-19\/current-situation.html?stat=num&measure=deaths_total&map=pt#a2"},{"key":"zoi250497r25","unstructured":"Respiratory Virus Detection Surveillance System (RVDSS). Respiratory virus trends in Canada. Accessed November 7, 2024. https:\/\/health-infobase.canada.ca\/respiratory-virus-detections\/#wb-cont"},{"key":"zoi250497r26","unstructured":"Walker? S, Guan? W, Freeman? J, Bolker? B, Flynn-Primrose? D. macpan2: fast and flexible compartmental modelling. R package version 1.12.0. Accessed November 14, 2024. https:\/\/canmod.github.io\/macpan2\/"},{"key":"zoi250497r27","unstructured":"Centers for Disease Control and Prevention (CDC). Data from: clinical characteristics of laboratory-confirmed COVID-19 hospitalizations from the COVID-NET surveillance system. 2024. Accessed September 21, 2023. https:\/\/www.cdc.gov\/covid\/php\/covid-net\/index.html"},{"key":"zoi250497r28","unstructured":"Canadian Institute for Health Information. COVID-19 hospitalization and emergency department statistics. Accessed December 2, 2022. https:\/\/www.cihi.ca\/en\/covid-19-hospitalization-and-emergency-department-statistics"},{"key":"zoi250497r29","unstructured":"Statistics Canada. Table 13-10-0114-01. Life expectancy and other elements of the complete life table, three-year estimates, Canada, all provinces except Prince Edward Island. Accessed January 5, 2024. doi:10.25318\/1310011401-eng"},{"key":"zoi250497r30","unstructured":"Government of Ontario. Ontario updating public health measures and guidance in response to Omicron. Updated 2021 Dec 30. Accessed July 31, 2024. https:\/\/news.ontario.ca\/en\/release\/1001386\/ontario-updating-public-health-measures-and-guidance-in-response-to-omicron"},{"key":"zoi250497r31","unstructured":"Kuang? S, Earl? S, Clarke? J, Zakaria? D, Demers? A, Aziz? S. Experiences of Canadians with long-term symptoms following COVID.? 2023. December 8, 2023. Accessed May 9, 2025. https:\/\/www150.statcan.gc.ca\/n1\/pub\/75-006-x\/2023001\/article\/00015-eng.htm"},{"key":"zoi250497r32","unstructured":"Link-Gelles? R. Effectiveness of COVID-19 (2023-2024 formula) vaccines. Slides presented at Advisory Committee on Immunization Practices meeting. June 27, 2024. Accessed November 14, 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/03-COVID-Link-Gelles-508.pdf"},{"key":"zoi250497r33","doi-asserted-by":"crossref","unstructured":"Public Health Agency of Canada. Canadian COVID-19 vaccination coverage report. Accessed November 24, 2024. https:\/\/health-infobase.canada.ca\/covid-19\/vaccination-coverage\/","DOI":"10.1186\/s12889-024-20854-6"},{"key":"zoi250497r34","unstructured":"Canada Health Infoway. 2021 Canadian digital health survey\u2014access to care. 2023. Accesssed January 5, 2024. https:\/\/insights.infoway-inforoute.ca\/access_to_care\/."},{"key":"zoi250497r36","unstructured":"Office of the Auditor General of Ontario. Chapter 3: immunization. https:\/\/www.auditor.on.ca\/en\/content\/annualreports\/arreports\/en14\/2014AR_en_web.pdf"},{"key":"zoi250497r37","unstructured":"Public Health Agency of Canada. Canadian COVID-19 vaccination safety report. 2024 Jan 19. https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/#a5"},{"key":"zoi250497r39","unstructured":"Statistics Canada. Canadian COVID-19 antibody and health survey. Accessed March 8, 2024. https:\/\/www23.statcan.gc.ca\/imdb\/p2SV.pl?Function=getSurvey&Id=1516982"},{"key":"zoi250497r40","unstructured":"Centers for Disease Control and Prevention (CDC). CDC vaccine price list as of July 1, 2024. 2024. https:\/\/www.cdc.gov\/vaccines-for-children\/php\/awardees\/current-cdc-vaccine-price-list.html."},{"key":"zoi250497r42","doi-asserted-by":"crossref","unstructured":"Sander? B, Mishra? S, Swayze? S, . Short-term and long-term healthcare costs attributable to diagnosed COVID-19 in Ontario; Canada: a population-based matched cohort study.? medRxiv. 2024;doi:10.1101\/2024.09.04.24313064","DOI":"10.1101\/2024.09.04.24313064"},{"key":"zoi250497r44","unstructured":"Canadian Institute for Health Information (CIHI). An overview of physician payments and cost per service. Accessed January 5, 2024. https:\/\/www.cihi.ca\/en\/health-workforce-in-canada-in-focus-including-nurses-and-physicians\/an-overview-of-physician"},{"key":"zoi250497r45","unstructured":"National Advisory Committee on Immunization. Recommendations on the use of conjugate pneumococcal vaccine - 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix. Accessed July 24, 2024. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines\/economic-evidence-supplementary-appendix.html"},{"key":"zoi250497r46","unstructured":"University of Western Ontario. Prescription dispensing fees. Accessed January 5, 2024. https:\/\/www.uwo.ca\/hr\/benefits\/your_benefits\/presc_fees.html"},{"key":"zoi250497r47","unstructured":"The Commonwealth Fund. International health care system profiles: Canada. Accessed January 5, 2024. https:\/\/www.commonwealthfund.org\/international-health-policy-center\/countries\/canada"},{"key":"zoi250497r51","unstructured":"Statistics Canada. Table 11-10-0239-01. Income of individuals by age group, sex and income source, Canada, provinces and selected census metropolitan areas. Accessed July 24, 2024. doi:10.25318\/1110023901-eng"},{"key":"zoi250497r54","unstructured":"Statistics Canada. Table 98-10-0022-01. Age (in single years), average age and median age and gender: Canada, provinces and territories, census divisions and census subdivisions. Accessed July 24, 2024. doi:10.25318\/9810002201-eng"},{"key":"zoi250497r56","unstructured":"Public Health Agency of Canada. Interpretation guide\u2014health economics. Accessed November 13, 2024. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/methods-process\/interpretation-guide-health-economics.html"},{"key":"zoi250497r57","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Accessed May 9, 2025. https:\/\/www.r-project.org\/."},{"key":"zoi250497r58","unstructured":"Department of Health and Social Care. JCVI statement on COVID-19 vaccination in 2025 and spring 2026. Accessed December 3, 2024. https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccination-in-2025-and-spring-2026-jcvi-advice\/jcvi-statement-on-covid-19-vaccination-in-2025-and-spring-2026"},{"key":"zoi250497r59","unstructured":"Prosser? LA. Economic analysis of an additional dose of the 2024-2025 COVID-19 vaccine. Slides presented at Advisory Committee on Immunization Practices meeting. 2024 October 23. Accessed November 14, 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/05-COVID-Prosser-508.pdf]"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835298\/miranda_2025_oi_250497_1749220881.35167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T15:30:45Z","timestamp":1749828645000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15534","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}